adenocarcinoma

When Anne Shimabukuro, a healthy mother of two, noticed a sharp pain in her left side in 2005, one that manifested itself when she ate, she immediately sought medical attention.  That led to a diagnosis of a malignant tumor in her pancreas.  She wasted no time in getting part of her pancreas removed.  It required a surgical procedure, followed by chemotherapy and radiation therapy.  Anne survived pancreatic cancer and today enjoys a healthy lifestyle.

That's right folks, we do anal gland removals!

An entire episode dedicated to butt stuff. Did we mention we talk about butts? If buttock-related surgeries give you the heebie-jeebies, seek cover no longer!

Twitter: @AllVetsAreOff

Merch: https://allvetsareoff.threadless.com/

Email: Allvetsareoff@gmail.com

After being diagnosed with Stage 3B lung cancer, Gary Brausen went through a painful journey that included radiation, aggressive chemotherapy and the loss of a lung; but he survived, and now works hard to help others with their cancer journeys.

This podcast will discuss the findings from a phase II trial of gemcitabine, cisplatin and PARP inhibitor therapy in germline BRCA/PALB2 mutant pancreatic cancer and discuss an optimal treatment strategy in this setting.

TRANSCRIPT

This JCO Podcast provides observations and commentary on the JCO article “A Randomized, Multi-Center, Phase II Trial of Gemcitabine, Cisplatin with or without Veliparib in Patients with Pancreas Adenocarcinoma and a Germline BRCA/ PALB2 Mutation” by O'Reilly et al. My name is Daniel Renouf, and I am a medical oncologist at the BC Cancer Vancouver Centre in Vancouver, Canada. My oncologic specialty is pancreatic cancer.

In this podcast, we will be discussing an important and evolving area that is changing our standard treatment strategies for pancreatic cancer. Progress has been slow for pancreatic adenocarcinoma, which is now the third leading cause of cancer-related death in North America and is projected to become the second leading cause of cancer-related death within the next decade. Modest gains in our treatments have been achieved with new chemotherapy combinations, including FOLFIRINOX and gemcitabine and nano-albumen bound-paclitaxel, yet still the majority of patients diagnosed with advanced disease will live for less than one year.

There is a critical need for improved treatment options as well as clinically relevant predictive markers to guide our therapeutic decision making. The first clinically important predictive marker in pancreatic cancer is germline BRCA/PALB2 mutation status, which is present in 5-9% of pancreatic adenocarcinomas. Multiple translational studies and case series have demonstrated distinct molecular features of these tumors, as well as unique clinical characteristics. Germline BRCA/PALB2 mutant pancreatic adenocarcinomas have been noted to be sensitive to platinum agents and be associated with a better prognosis. Despite this data, and a general acceptance within the community that platinum agents are the preferred therapies in this setting, there is minimal prospective trial data specifically assessing the activity of platinum combinations in germline BRCA/PALB2 mutant pancreatic adenocarcinoma.

At a plenary session at ASCO 2019 and its subsequent publication, the POLO trial assessed the role of maintenance therapy with a poly-ADP ribose polymerase (PARP) inhibitor (olaparib), compared to placebo, in patients with metastatic pancreatic adenocarcinoma and germline mutations in BRCA/PALB2 who had responded or had stable disease after initial therapy with FOLFIRINOX. This was a positive trial, demonstrating that maintenance olaparib significantly improved progression-free survival compared to placebo. There was no difference noted in overall survival, but this data was not yet mature. The role of combining a PARP inhibitor with platinum-based chemotherapy as upfront treatment in this patient population is yet to be defined.  A previous Phase I trial of gemcitabine, cisplatin and the PARP inhibitor veliparib determined a recommended phase II dose for velipirib in this combination and demonstrated promising efficacy in germline BRCA-mutant pancreatic adenocarcinoma.

In the article that accompanies this podcast, Dr. O’Reilly and colleagues report on the results of a phase II prospective trial comparing gemcitabine and cisplatin versus gemcitabine, cisplatin and veliparib in patients with advanced pancreatic adenocarcinoma with germline aberrations in BRCA/PALB2. In the trial, patients with locally advanced or metastatic pancreatic cancer who had not received chemotherapy in the advanced setting, had a good performance status, and who harbored germline aberrations in BRCA/PALB2 were randomized.

A total of 50 patients were enrolled, and the results demonstrated good efficacy in both arms, with a response rate of 74.1% in the veliparib arm and 65.2% in the control arm. Median progression-free survival was 10.1 months and 9.7 in the veliparib and non-veliparib arms respectively, and median overall survival was 15.5 and 16.4 months. Of note, for the entire cohort, 2-year overall survival was notably high at 30.6%, and 3-year overall survival was 17.8%. Grade 3-4 toxicities, including neutropenia, thrombocytopenia, and anemia were greater in the veliparib arm.

The authors concluded that gemcitabine and cisplatin demonstrated significant activity in BRCA/PALB2 germline mutant pancreatic adenocarcinoma, and the addition of concurrent veliparib did not improve efficacy. Given this promising data, it was concluded that gemcitabine and cisplatin should be considered a standard treatment for BRCA/PALB2 germline mutant pancreatic adenocarcinoma.

This is an important trial, as it is one of the first to specifically assess platinum chemotherapy prospectively in this patient population and has important implications for treatment strategies for pancreatic cancer, the first of which is that testing for germline BRCA/PALB2 mutations should now be considered standard of care for all newly diagnosed pancreatic adenocarcinomas. Not only does this have important treatment implications for the patient; it also has strong relevance to the patients’ family members, as it was found to also harbor a germline BRCA/PALB2 mutation. Screening and potential prevention strategies could be considered for other cancers, such as breast and ovarian.

Secondly, if a patient is found to have a germline BRCA/PALB2 mutation, the data from this trial in combination with the body of literature in this setting would suggest that first line therapy with a platinum agent should be considered. In this setting, one could consider either FOLFIRINOX or gemcitabine and cisplatin. The efficacy of gemcitabine and nano albumen bound-paclitaxel in this patient population is not clearly defined, but in the context of data from other disease sites also demonstrating increased sensitivity to platinum in this patient population, and given many patients with advanced pancreatic adenocarcinoma are often not well enough to received multiple lines of therapy, a first line platinum combination should be strongly considered. Thirdly, this trial demonstrates that there is no additional benefit from adding a PARP inhibitor to chemotherapy in this setting, but there is added toxicity, and thus this strategy should not be considered at this time.

Finally, given that toxicity from platinum-based chemotherapy is cumulative, the question of an optimal maintenance strategy remains. The POLO trial demonstrated that there is activity and a progression-free survival benefit when using olaparib as a maintenance post upfront platinum-based chemotherapy when compared to placebo, and therefore this represents one potential strategy. One criticism of the POLO trial is that many centers do not stop treatment and instead continue therapy without the platinum after an initial response. In patients responding to initial treatment with FOLFIRINOX, maintenance FOLFIRI is often considered. Data from a second line trial of FOLFIRI with or without veliparib presented as a poster discussion at ASCO 2019 by Dr. Chiorean and colleagues noted that BRCA/PALB2 mutant tumors also appear to have increased sensitivity to FOLFIRI. At this time, the optimal maintenance strategy after upfront platinum therapy is yet to be fully defined, and further research in this setting is needed. In addition, to what extent these strategies should be applied to patients with pancreatic adenocarcinomas that are germline BRCA/PALB2 wildtype but have other homologous recombination deficiency defects requires further investigation.

In summary, this is an exciting time in pancreatic adenocarcinoma as we now have a clinically important biomarker to guide treatment strategies. This important trial by Dr. O’Reilly and colleagues further solidifies the importance of BRCA/PALB2 germline testing in pancreatic adenocarcinoma and that first line platinum-based chemotherapy should be considered in these patients.

This concludes this JCO Podcast. Thank you for listening.

A Surgeon’s Perspective: Health Begins in the Gut!

Today we are thrilled and blessed to speak with Christopher C. Smith, MD, FACS, a board-certified general surgeon that has practiced in Albany GA since 1983. A native of Tifton, Georgia, Dr. Smith earned a B.S. degree from the University of Georgia, and then earned a Medicine doctorate degree from the Medical College of Georgia in Augusta.

Dr. Smith is one of the pioneers of laparoscopic surgery and Albany Surgical/Southern Surgery Center serves as a worldwide center of excellence for robotic surgery, bariatric weight loss surgery and alternatives, and cutting-edge reflux treatments such as Nissen and Linx procedures along with many other types of general surgery. 

Dr. Smith long ago distinguished himself as a brilliant surgeon, but his lifelong fascination with the role of nutrition and exercise in health certainly sets him apart from his peers. His patients love the fact that he sees surgery as the last option to address their health challenges, and only after dietary and lifestyle interventions have failed to produce the desired outcome.

He believes as we do that good health begins and ends in the gut with a healthy gut biome, and his adoring patients are living proof of this truth. Dr. Smith is indeed a rare gem in the world of modern medicine.  We look forward to hearing his incredible insights to Reflux, PPI's and the Link to Cancer.  

Product Deal of the Week:  Cold and Flu Health Kit for only $85, that is a savings of over 20%.  Just use the coupon code NOFLU4U at checkout.

A Surgeon’s Perspective: Health Begins in the Gut!

Today we are thrilled and blessed to speak with Christopher C. Smith, MD, FACS, a board-certified general surgeon that has practiced in Albany GA since 1983. A native of Tifton, Georgia, Dr. Smith earned a B.S. degree from the University of Georgia, and then earned Medicine doctorate degree from the Medical College of Georgia in Augusta.

Dr. Smith is one of the pioneers of laparoscopic surgery and Albany Surgical/Southern Surgery Center serves as a worldwide center of excellence for robotic surgery, bariatric weight loss surgery and alternatives, and cutting edge reflux treatments such as Nissen and Linx procedures along with many other types of general surgery. 

Dr. Smith long ago distinguished himself as a brilliant surgeon, but his lifelong fascination with the role of nutrition and exercise in health certainly sets him apart from his peers. His patients love the fact that he sees surgery as the last option to address their health challenges, and only after dietary and lifestyle interventions have failed to produce the desired outcome.

He believes as we do that good health begins and ends in the gut with a healthy gut biome, and his adoring patients are living proof of this truth. Dr. Smith is indeed a rare gem in the world of modern medicine.  We look forward to hearing his incredible insights to Reflux, PPI's and the Link to Cancer.  

Product Offer: Get a Free bottle of Colostrum when you purchase the Digestive Health Pack which includes: Essential Digestion, Essential Flora, L-Glutamine and Liver CS Plus.  Add both products to your cart and use this coupon code to receive your BOGO discount: GUTHELP.

Dr. Tom (Thomas Incledon) is the founder and CEO of Causenta Wellness, and the Causenta Cancer Treatment Center in Scottsdale, Arizona. Doctor Tom's mission at Causenta is to "Kill cancer once and for all with minimal side effects". Join Doctor Tom and the team at Causenta as he answers important questions about cancer treatment and wellness. Doctor Tom dives into breakthrough discussions on breast cancer, colon cancer, prostate cancer, pancreatic cancer, glioblastoma multiforme, Lung Cancer, Lung Cancer, Sarcoma, Small Intestinal Cancer, Adenocarcinoma, Adenosquamous Cancer, Ampullary cancer, Bladder Cancer, Cervical Cancer, Gall Bladder Cancer, Non-Hodgkins lymphoma B Cell, Ocular Melanoma, Ewing's sarcoma

When I was pregnant with my daughter, my husband was diagnosed with adenocarcinoma. We knew the prognosis was not good, so we decided to have many uncomfortable conversations about what this fight would look like together and after he was gone. It was heart wrenching to make those kinds of decisions, but I'm so glad that we did. From the moment Keith experienced his first symptom to the time he passed away, it had only been three months. It was shocking and emotionally complicated since I had a two-year-old to care for and a baby that wasn't due for another month. I spent the month between his death and Libby's birth in a dark and angry place. I had lots of questions and very freely told God that he had messed up. And then Libby was born and light started shining through the cracks in my heart; this little baby reminded me that there was good and there was hope, even when my heart was so very broken. We experienced so much grace in the months Keith was sick and after he died. People brought food, cared for the kids, and cleaned my house. My kids brought laughter to our house. Being widowed and a single mom was never the plan for my life, but the grace, the good things, remind me that there is hope and that my story isn't over.

Becky's Fun Question Answers:
• What are you loving right now? Golden Girls on Hulu!
• What’s your favorite food/meal/snack? Queso (always) and Underwood Cellars' Pinot Noir
• What are you doing to take care of yourself? Bubble baths and glasses of wine when I make the time for it. Waking up an hour before the kids to have time for myself.
• What are you doing to be brave? Getting to know who I am and living confidently based on my strengths and weaknesses (especially not being ashamed of my weaknesses)

Connect with Becky:
BLOG: BeckyLMcCoy.com
FACEBOOK: facebook.com/BeckyLMcCoy
TWITTER: twitter.com/BeckyLMcCoy
INSTAGRAM: instagram.com/BeckyLMcCoy
PINTEREST: pinterest.com/BeckyLMcCoy
NEWSLETTER: BeckyLMcCoy.com/email 

Share your Sucker Punched story at BeckyLMcCoy.com/Submissions Please subscribe to and rate this podcast to help others find Sucker Punched.

NOTE: Sucker Punched is the podcast formerly known as Stories of Unfolding Grace

Hosts: Vincent Racaniello, Michael Schmidt, Elio Schaechter and Michele Swanson.  

The TWiM team discusses how measles vaccination protects against other infectious diseases, and links between bacterial biofilms and colon cancer.

Subscribe to TWiM (free) on iTunes, Stitcher, RSS, or by email. You can also listen on your mobile device with the Microbeworld app.

Links for this episode

Measles vaccination prevents all-cause infectious disease (Science)

Master of contagion (The Loom)

Video: Measles incidence to immunomodulation (Science)

FAQ: Adult vaccines

Metabolism links biofilms and colon cancer (Cell Metab)

Scripps Center for Metabolomics

Scripps metabolite database

Image credit

Sponsors for this episode: SciMedSolutions, ICAAC-ICC

Send your microbiology questions and comments (email or mp3 file) to twim@twiv.tv, or call them in to 908-312-0760. You can also post articles that you would like us to discuss at microbeworld.org and tag them with twim.